vs

Side-by-side financial comparison of Comstock Holding Companies, Inc. (CHCI) and STANDARD BIOTOOLS INC. (LAB). Click either name above to swap in a different company.

Comstock Holding Companies, Inc. is the larger business by last-quarter revenue ($23.9M vs $19.6M, roughly 1.2× STANDARD BIOTOOLS INC.). Comstock Holding Companies, Inc. runs the higher net margin — 56.3% vs -177.4%, a 233.7% gap on every dollar of revenue. On growth, Comstock Holding Companies, Inc. posted the faster year-over-year revenue change (41.5% vs -11.5%). Over the past eight quarters, Comstock Holding Companies, Inc.'s revenue compounded faster (50.0% CAGR vs -12.2%).

The Comstock Lode is a lode of silver ore located under the eastern slope of Mount Davidson, a peak in the Virginia Range in Virginia City, Nevada, which was the first major discovery of silver ore in the United States and named after Canadian miner Henry Comstock.

Standard BioTools Inc., previously known as Fluidigm Corp., is an American life science tools company that offers analytical mass cytometry systems for flow cytometry and tissue imaging, along with associated assays and reagents, as well as an automated genomic analysis instrument and a variety of microfluidic arrays, or integrated fluidic circuits (IFCs), and consumables with fully kitted reagents. Custom assays and services are available with all systems and applications.

CHCI vs LAB — Head-to-Head

Bigger by revenue
CHCI
CHCI
1.2× larger
CHCI
$23.9M
$19.6M
LAB
Growing faster (revenue YoY)
CHCI
CHCI
+53.0% gap
CHCI
41.5%
-11.5%
LAB
Higher net margin
CHCI
CHCI
233.7% more per $
CHCI
56.3%
-177.4%
LAB
Faster 2-yr revenue CAGR
CHCI
CHCI
Annualised
CHCI
50.0%
-12.2%
LAB

Income Statement — Q4 FY2025 vs Q3 FY2025

Metric
CHCI
CHCI
LAB
LAB
Revenue
$23.9M
$19.6M
Net Profit
$13.5M
$-34.7M
Gross Margin
35.5%
48.5%
Operating Margin
32.4%
-168.5%
Net Margin
56.3%
-177.4%
Revenue YoY
41.5%
-11.5%
Net Profit YoY
30.5%
-28.8%
EPS (diluted)
$-0.09

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CHCI
CHCI
LAB
LAB
Q4 25
$23.9M
Q3 25
$13.3M
$19.6M
Q2 25
$13.0M
$21.8M
Q1 25
$12.6M
$40.8M
Q4 24
$16.9M
Q3 24
$13.0M
$22.1M
Q2 24
$10.8M
$22.5M
Q1 24
$10.6M
$45.5M
Net Profit
CHCI
CHCI
LAB
LAB
Q4 25
$13.5M
Q3 25
$541.0K
$-34.7M
Q2 25
$1.4M
$-33.5M
Q1 25
$1.6M
$-26.0M
Q4 24
$10.3M
Q3 24
$2.4M
$-26.9M
Q2 24
$946.0K
$-45.7M
Q1 24
$910.0K
$-32.2M
Gross Margin
CHCI
CHCI
LAB
LAB
Q4 25
35.5%
Q3 25
11.0%
48.5%
Q2 25
19.0%
48.8%
Q1 25
18.6%
48.4%
Q4 24
33.4%
Q3 24
26.3%
54.9%
Q2 24
17.2%
46.1%
Q1 24
16.5%
53.1%
Operating Margin
CHCI
CHCI
LAB
LAB
Q4 25
32.4%
Q3 25
5.0%
-168.5%
Q2 25
13.7%
-118.1%
Q1 25
13.7%
-80.8%
Q4 24
30.1%
Q3 24
21.8%
-120.9%
Q2 24
11.4%
-134.5%
Q1 24
10.8%
-132.2%
Net Margin
CHCI
CHCI
LAB
LAB
Q4 25
56.3%
Q3 25
4.1%
-177.4%
Q2 25
11.1%
-153.7%
Q1 25
12.6%
-63.8%
Q4 24
61.1%
Q3 24
18.3%
-122.0%
Q2 24
8.8%
-203.3%
Q1 24
8.6%
-70.6%
EPS (diluted)
CHCI
CHCI
LAB
LAB
Q4 25
Q3 25
$-0.09
Q2 25
$-0.09
Q1 25
$-0.07
Q4 24
Q3 24
$-0.07
Q2 24
$-0.12
Q1 24
$0.09
$-0.27

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CHCI
CHCI
LAB
LAB
Cash + ST InvestmentsLiquidity on hand
$31.3M
$129.4M
Total DebtLower is stronger
Stockholders' EquityBook value
$70.0M
$399.7M
Total Assets
$85.0M
$539.6M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CHCI
CHCI
LAB
LAB
Q4 25
$31.3M
Q3 25
$26.2M
$129.4M
Q2 25
$30.5M
$158.6M
Q1 25
$28.3M
$150.9M
Q4 24
$28.8M
Q3 24
$21.1M
$210.6M
Q2 24
$17.4M
$269.8M
Q1 24
$16.2M
$287.1M
Total Debt
CHCI
CHCI
LAB
LAB
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
$55.2M
Q2 24
$55.1M
Q1 24
$55.0M
Stockholders' Equity
CHCI
CHCI
LAB
LAB
Q4 25
$70.0M
Q3 25
$56.3M
$399.7M
Q2 25
$55.5M
$424.5M
Q1 25
$53.7M
$454.6M
Q4 24
$52.4M
Q3 24
$41.7M
$489.3M
Q2 24
$39.2M
$510.3M
Q1 24
$37.9M
$577.3M
Total Assets
CHCI
CHCI
LAB
LAB
Q4 25
$85.0M
Q3 25
$67.6M
$539.6M
Q2 25
$65.2M
$557.0M
Q1 25
$62.8M
$579.6M
Q4 24
$64.9M
Q3 24
$52.2M
$681.5M
Q2 24
$48.6M
$708.7M
Q1 24
$46.8M
$777.7M
Debt / Equity
CHCI
CHCI
LAB
LAB
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
0.11×
Q2 24
0.11×
Q1 24
0.10×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CHCI
CHCI
LAB
LAB
Operating Cash FlowLast quarter
$4.8M
$-22.2M
Free Cash FlowOCF − Capex
$-23.1M
FCF MarginFCF / Revenue
-118.1%
Capex IntensityCapex / Revenue
4.5%
Cash ConversionOCF / Net Profit
0.36×
TTM Free Cash FlowTrailing 4 quarters
$-111.1M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CHCI
CHCI
LAB
LAB
Q4 25
$4.8M
Q3 25
$-3.2M
$-22.2M
Q2 25
$2.2M
$-20.7M
Q1 25
$582.0K
$-30.3M
Q4 24
$10.7M
Q3 24
$3.9M
$-27.9M
Q2 24
$1.3M
$-39.0M
Q1 24
$-2.2M
$-62.5M
Free Cash Flow
CHCI
CHCI
LAB
LAB
Q4 25
Q3 25
$-23.1M
Q2 25
$-22.6M
Q1 25
$-35.3M
Q4 24
Q3 24
$-30.1M
Q2 24
$-41.0M
Q1 24
$-63.3M
FCF Margin
CHCI
CHCI
LAB
LAB
Q4 25
Q3 25
-118.1%
Q2 25
-103.6%
Q1 25
-86.6%
Q4 24
Q3 24
-136.4%
Q2 24
-182.2%
Q1 24
-138.9%
Capex Intensity
CHCI
CHCI
LAB
LAB
Q4 25
Q3 25
4.5%
Q2 25
8.7%
Q1 25
12.4%
Q4 24
Q3 24
10.2%
Q2 24
8.6%
Q1 24
1.7%
Cash Conversion
CHCI
CHCI
LAB
LAB
Q4 25
0.36×
Q3 25
-5.96×
Q2 25
1.51×
Q1 25
0.37×
Q4 24
1.03×
Q3 24
1.63×
Q2 24
1.35×
Q1 24
-2.46×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

CHCI
CHCI

Related Party$22.1M92%
Nonrelated Party$1.9M8%

LAB
LAB

Consumables$8.7M45%
Services And Other Revenue$5.8M29%
Instruments$5.1M26%

Related Comparisons